UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 191

Sortiert nach

Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome

Clinical cancer research, 2015-11, Vol.21 (22), p.5164-5172

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Advances in Hematology, 2022-01, Vol.2022, p.5581772-10

2022

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas

Critical reviews in oncology/hematology, 2021-11, Vol.167, p.103496-103496, Article 103496

2021

Link zum Volltext

Verfügbarkeit prüfen

Chlamydial infection: the link with ocular adnexal lymphomas

Nature reviews. Clinical oncology, 2009-12, Vol.6 (12), p.678-678

2009

Link zum Volltext

Verfügbarkeit prüfen

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

1st ed. 2018., 2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to A. Korfel et al

Journal of clinical oncology, 2016-05, Vol.34 (15), p.1830-1831

2016

Link zum Volltext

Verfügbarkeit prüfen

Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?

The American journal of surgical pathology, 2012-11, Vol.36 (11), p.1609-1618

2012

Link zum Volltext

Verfügbarkeit prüfen

Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.2908-2908

2019

Link zum Volltext

Verfügbarkeit prüfen

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Clinical lymphoma, myeloma and leukemia, 2013-09, Vol.13, p.S382-S383

2013

Link zum Volltext

Verfügbarkeit prüfen

Activity of Clarithromycin in Mucosa-Associated Lymphoid Tissue-Type Lymphomas

Chest, 2011-03, Vol.139 (3), p.724-725

Ferreri, Andrés J.M., MD

2011

Link zum Volltext

Verfügbarkeit prüfen

INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Evolving Treatments for Primary Central Nervous System Lymphoma

American Society of Clinical Oncology educational book, 2019-01 (39), p.454-466

2019

Link zum Volltext

Verfügbarkeit prüfen

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Blood, 2018-11, Vol.132 (Supplement 1), p.4162-4162

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood, 2021-11, Vol.138 (Supplement 1), p.131-131

2021

Link zum Volltext

Verfügbarkeit prüfen

“Miro” Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20073-e20073

2020

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma

Blood, 2012-11, Vol.120 (21), p.4860-4860

2012

Link zum Volltext

Verfügbarkeit prüfen

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood, 2018-11, Vol.132 (Supplement 1), p.2925-2925

2018

Link zum Volltext

Verfügbarkeit prüfen

S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R‐POLA‐MINI‐CHP AND R‐MINI‐CHOP

HemaSphere, 2023-08, Vol.7 (S3), p.e91359ec-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

Blood, 2019-11, Vol.134 (Supplement_1), p.2891-2891

2019

Link zum Volltext

Verfügbarkeit prüfen

MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

Blood, 2019-11, Vol.134 (Supplement_1), p.5092-5092

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 191

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(14)
Lymphoma
(11)
Female
(9)
Hematology, Oncology And Palliative Medicine
(9)
Male
(8)
Adult
(7)
Chemotherapy
(6)
Middle Aged
(6)
Prognosis
(6)
Aged
(5)
Treatment Outcome
(5)
Adolescent
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Clinical Trials
(3)
Drug Development
(3)
Hematology
(3)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(3)
Oncology
(3)
Aged, 80 And Over
(2)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas

Chlamydial infection: the link with ocular adnexal lymphomas

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Reply to A. Korfel et al

Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?

Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial

Activity of Clarithromycin in Mucosa-Associated Lymphoid Tissue-Type Lymphomas

INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Evolving Treatments for Primary Central Nervous System Lymphoma

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

“Miro” Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R‐POLA‐MINI‐CHP AND R‐MINI‐CHOP

Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

Aktive Filter

Suchergebnisse filtern